金水宝胶囊对COPD稳定期患者肺功能和免疫功能的影响

Effect of Jinshuibao Capsule on Pulmonary Function and Immune Function in Stable Patients with Chronic Obstructive Pulmonary Disease

摘要:

目的: 探讨金水宝胶囊对慢性阻塞性肺疾病(COPD)稳定期患者肺功能和免疫功能(Th17/Treg)的影响. 方法: 将76例COPD 患者随机分为两组,对照组38例仅吸入噻托溴铵吸入剂,每日1吸;治疗组38例加服金水宝胶囊,每次3粒,每日3次,疗程为3个月.观察两组的临床疗效,治疗前后临床症状积分、肺功能和免疫功能(Th17/Treg)的变化. 结果: ①治疗组、对照组总有效率分别为88.6%和77.1%(P<0.05).②治疗后治疗组各症状积分显著下降 (P<0.01),治疗组改善临床症状优于对照组 (P<0.01).③治疗后治疗组第一秒用力肺活量(FEV₁),FEV₁%和1秒用力呼气量占用力肺活量百分比(FEV₁/FVC%)升高(P<0.01),与对照组比较差异有统计学意义(P<0.05,P<0.01).④治疗后治疗组Th17%和Th17/Treg升高(P<0.01),与对照组比较差异有统计学意义(P<0.05). 结论: 金水宝胶囊联合噻托溴铵吸入剂治疗COPD稳定期的疗效确切,可明显地改善患者的临床症状和肺功能,其作用机制可能是通过调节外周血Th17/Treg而改善患者的免疫功能.

Abstract:

Objective: To investigate the effect of Jinshuibao capsule on pulmonary function and immune function (Th17/Treg) in stable patients with chronic obstructive pulmonary disease (COPD). Method: Seventy-six patients with COPD were randomly divided into 2 groups;38 patients in the control group took tiotropium bromide powder for inhalation alone, 18 μg daily;38 patients in the treatment group added Jinshuibao capsule, 3 capsules each time, 3 times daily;the patients in two groups received 3-month period of treatment. Clinical efficacy, clinical symptoms, pulmonary function and immune function (Th17/Treg) changes in two groups were observed before and after the treatment. Result: ①The total effective rate of the treatment group and the control group were 88.6% and 77.1% respectively(P<0.05). ②After the treatment, symptom score of the treatment group was significantly decreased (P<0.01), and the improvement of clinical symptoms in the treatment group was better than that in the control group (P<0.01). ③After the treatment, forced expiratory rolume in one second(FEV₁), FEV₁% and FEV₁/forced vital capacity(FVC)% in the treatment group were increased (P<0.01), there was statistical difference as compared with that in the control group (P<0.05, P<0.01). ④After the treatment, Th17% and Th17/Treg in the treatment group were increased (P<0.01), there was statistical difference as compared with that in the control group (P<0.05). Conclusion: Jinshuibao capsule combined with tiotropium bromide powder for inhalation had clear efficacy in improving patient's clinical symptoms and pulmonary function in stable COPD. The mechanism may be achieved by adjusting peripheral Th17/Treg ratio and improving patient's immune function.